Difference between revisions of "Team:CPU CHINA"
BaoqiangCPU (Talk | contribs) |
|||
| (35 intermediate revisions by 2 users not shown) | |||
| Line 28: | Line 28: | ||
<p><br> <br></p> | <p><br> <br></p> | ||
<p><br> <br></p> | <p><br> <br></p> | ||
| + | <p><br> <br></p> | ||
| + | |||
<img src="https://static.igem.org/mediawiki/2017/9/97/T--CPU_CHINA--mainpage_new.png" width = "1300"> | <img src="https://static.igem.org/mediawiki/2017/9/97/T--CPU_CHINA--mainpage_new.png" width = "1300"> | ||
</center> | </center> | ||
| Line 33: | Line 35: | ||
<center class="pagee pagee1"> | <center class="pagee pagee1"> | ||
<p><br> <br></p> | <p><br> <br></p> | ||
| + | |||
| + | |||
<h5 style="padding: 0px; margin: 5px;">Our HEAD-Treg</h5> | <h5 style="padding: 0px; margin: 5px;">Our HEAD-Treg</h5> | ||
| − | <video src="https://static.igem.org/mediawiki/2017/ | + | <video src="https://static.igem.org/mediawiki/2017/5/5a/T--CPU_CHINA--V123.mp4" controls="controls" class="video" width = "55%"></video> |
</center> | </center> | ||
<center class="pagee pagee2"> | <center class="pagee pagee2"> | ||
| − | + | <p><br> <br></p> | |
<p><br> <br></p> | <p><br> <br></p> | ||
<h5 style="padding: 0px; margin: 0px;">Description</h5> | <h5 style="padding: 0px; margin: 0px;">Description</h5> | ||
| Line 48: | Line 52: | ||
inflammatory environment, which enables them to play their role of immunosuppression in lesions more | inflammatory environment, which enables them to play their role of immunosuppression in lesions more | ||
efficiently and more stably. <br>These two redirections of the two different but interrelated systems on Tregs ensure this novel therapy a promising anti-RA effect. </h4> | efficiently and more stably. <br>These two redirections of the two different but interrelated systems on Tregs ensure this novel therapy a promising anti-RA effect. </h4> | ||
| − | + | <p><br> <br></p> | |
| + | |||
<center class="footer-left"> | <center class="footer-left"> | ||
| − | <p class="footer-links"> | + | <p class="footer-links" style="text-align:center;"> |
<a target="_blank" href="https://www.cpu.edu.cn"> | <a target="_blank" href="https://www.cpu.edu.cn"> | ||
<img class="sponsors" src="https://static.igem.org/mediawiki/2017/5/52/T--CPU_CHINA--cpu_logo_new_1.png"></a> | <img class="sponsors" src="https://static.igem.org/mediawiki/2017/5/52/T--CPU_CHINA--cpu_logo_new_1.png"></a> | ||
| Line 63: | Line 68: | ||
<a target="_blank" href="https://www.genscript.com/"> | <a target="_blank" href="https://www.genscript.com/"> | ||
<img class="sponsors" src="https://static.igem.org/mediawiki/2017/3/38/T--CPU_CHINA--cpu_logogenscript.png"></a> | <img class="sponsors" src="https://static.igem.org/mediawiki/2017/3/38/T--CPU_CHINA--cpu_logogenscript.png"></a> | ||
| + | <a target="_blank" href="javascript:();"> | ||
| + | <img class="sponsors" src="https://static.igem.org/mediawiki/2017/d/da/Cyva.jpg"></a> | ||
| + | <a target="_blank" href="javascript:();"> | ||
| + | <img class="sponsors" src="https://static.igem.org/mediawiki/2017/1/17/T--CPU_CHINA--cpu_sponsors_11_contect_2.png"></a> | ||
</p> | </p> | ||
</center> | </center> | ||
| Line 137: | Line 146: | ||
.sponsors { | .sponsors { | ||
margin: 2.5px; | margin: 2.5px; | ||
| − | width: | + | width: 150px; |
} | } | ||
Latest revision as of 03:20, 2 November 2017
Our HEAD-Treg
Description
Rheumatoid arthritis (RA) is a serious chronic, inflammatory and systemic autoimmune disease.
It is of great essence to develop a novel cell-targeted therapy for RA
because there is no radical cure
for RA for the time being.
To solve the problems existing in the current treatment of RA, we design and build a brand new immunotherapy.
FOXP3+ regulatory T cells(Tregs), which can suppress and regulate immune reactions, are modified
utilizing a lentiviral vector system to express a chimeric antigen receptor(CAR) targeting inflammatory cells associated with RA.
Meanwhile, we insert the Syn-Notch receptor to activate the functional stability pathway of Tregs in the
inflammatory environment, which enables them to play their role of immunosuppression in lesions more
efficiently and more stably.
These two redirections of the two different but interrelated systems on Tregs ensure this novel therapy a promising anti-RA effect.
